#USA #Bethesda #Liquid Biopsy #SOPHiA GENETICS #Precision for Medicine

Precision for Medicine Partners with SOPHiA GENETICS

In a significant move aimed at enhancing biopharma services, Precision for Medicine has announced a strategic partnership with SOPHiA GENETICS. This collaboration is set to leverage the advanced capabilities of the SOPHiA DDM™ platform and its liquid biopsy functions to improve biomarker discovery and precision medicine initiatives.

The integration of cutting-edge AI-driven analyses and clinical study solutions is anticipated to expedite drug development processes, enabling biopharma companies to bring targeted therapies to market more swiftly. With the rollout of this partnership, Precision for Medicine is optimistic about providing biopharma firms with refined tools for clinical planning, patient stratification, and data analysis, thus significantly improving their overall service offerings.

Dr. Darren Davis, Senior Vice President at Precision for Medicine, highlights the potential impact of this collaboration: "By utilizing the AI-driven algorithms of the SOPHiA DDM™ platform, we can analyze complex multimodal data including genomic, radiological, and clinical data. This capability will allow biopharma companies to effectively identify and target the most suitable patient groups for clinical trials, accelerating both biomarker discovery and diagnostic capabilities. This is particularly crucial in oncology, rare diseases, and genetic disorders, where understanding the distinct genomic characteristics of each patient paves the way for more targeted therapies."

As part of this partnership, Precision for Medicine will also offer MSK-ACCESS® powered with SOPHiA DDM™, an innovative liquid biopsy test supported by AstraZeneca. This internationally employed test provides a wealth of genomic data, enabling retrospective analysis of clinical trial data and improving patient stratification. This data-rich approach allows biopharma companies to refine their clinical study plans, better understand previous treatment responses, and ultimately optimize their drug development strategies.

"The partnership allows us to integrate the SOPHiA DDM™ platform and MSK-ACCESS® into our service portfolio, giving biopharma companies the tools they need to accurately identify the right patient groups for inclusion in clinical trials," Davis remarked. Through the application of AI algorithms and machine learning, Precision for Medicine aims to discover biomarkers and genomic signatures that facilitate more efficient and targeted studies.

An integrated service offering under one roof is another key advantage of this partnership. In addition to data analysis and clinical study support, Precision for Medicine will provide wet lab services, streamlining operations for biopharma clients. This comprehensive approach simplifies the process for customers, allowing them to rely on a single solution provider while utilizing the collaborative strengths of Precision for Medicine and SOPHiA GENETICS.

Ross Muken, President of SOPHiA GENETICS, expressed enthusiasm about the collaboration: "Our partnership with Precision for Medicine enables us to expand the reach and impact of our SOPHiA DDM™ platform, delivering actionable insights in real time across the spectrum of clinical studies. Together, we can provide biopharma companies with comprehensive, data-driven capabilities that accelerate the market introduction of precision therapies."

The robust experience of Precision for Medicine in clinical trial settings—including biomarker testing and laboratory services—combined with the AI-based genomic analysis tools of SOPHiA GENETICS, creates a powerful, comprehensive solution for biopharma companies. Clients now have the opportunity to expedite drug development with a seamless solution for both data analysis and clinical support, facilitating a more efficient transition from preclinical research to market readiness.

This partnership is a significant driver of innovation in precision medicine, equipping biopharma companies with the instruments necessary to better understand patients' genetic makeup and develop personalized treatments for complex diseases. It opens up the possibility for treatments tailored to specific genomic profiles, aiming to improve outcomes, patient satisfaction, and overall market value of their products. With a patient-centered approach, this collaboration is poised to usher in breakthroughs in oncology, rare diseases, and other areas with substantial unmet medical needs.